Drug Research
EC Authorizes Opdualag From BMS As A Melanoma Treatment
The fixed-dose combination Opdualag (nivolumab and relatlimab) from Bristol Myers Squibb (BMS) has received clearance from the European Commission for use as the first-line therapy for advanced unresectable or metastatic melanoma.
Patients aged 12 years and older who have cancer...
News
GAVI Funds To Enable Quick Finances For The Next Pandemic
According to Chief Executive Seth Berkley of the global vaccination alliance GAVI, the organisation has set up financial structures that would enable it to quickly access pledged donor cash in the event that it needs to purchase vaccines for...
Drug Research
Bluebird Hits $3m Mark With Gene Therapy After FDA Approval
Within one firm, the title of most costly treatment in the world has changed hands within a month.
Bluebird Bio has received an FDA fast clearance for Skysona, also known as eli-cel, for the uncommon neurological condition cerebral adrenoleukodystrophy (CALD),...
Drug Research
First Next-Gen Parkinsons Med To Be Made By Neuron23, QIAGEN
QIAGEN and Neuron23TM Inc., an early-stage biotechnology company focused on creating precision medications for genetically defined neurological and immunological illnesses, have announced a partnership to create a companion diagnostic for Neuron23's LRRK2 inhibitor for Parkinson's disease.
According to the terms...
Drug Research
Australia Permits New Treatment For Rare Bile Duct Cancer
Australia has authorised the use of a new targeted therapy for the treatment of cholangiocarcinoma, a rare bile duct cancer. The Therapeutic Goods Administration (TGA) has granted PEMAZYRE (pemigatinib) provisional approval for the treatment of adult patients with metastatic...
Drug Research
Beyfortus From Sanofi And Astrazeneca Is Supported By RSV
Beyfortus has received approval from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency to treat lower respiratory tract sickness caused by the respiratory syncytial virus (RSV) in neonates and young children.
If authorised, Beyfortus,...
Drug Research
canSERV, EU Cluster Effort, Offers Cancer Study In Europe
Brussels marks the beginning of the European canSERV initiative, which aims to defragment the European cancer research landscape. CanSERV will give academia and business exposure to cross-cutting services and assistance from fundamental science up to clinical application over the...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.
Must read